Royal Bank of Canada grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 3.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,152 shares of the biotechnology company’s stock after purchasing an additional 1,864 shares during the period. Royal Bank of Canada owned about 0.14% of United Therapeutics worth $35,075,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Elmind Capital LP lifted its position in shares of United Therapeutics by 36.4% during the first quarter. Elmind Capital LP now owns 15,000 shares of the biotechnology company’s stock worth $8,895,000 after purchasing an additional 4,000 shares in the last quarter. Eversept Partners LP grew its holdings in shares of United Therapeutics by 4.6% in the first quarter. Eversept Partners LP now owns 264,271 shares of the biotechnology company’s stock valued at $156,707,000 after purchasing an additional 11,679 shares in the last quarter. Excelsior Advisor Network LLC purchased a new stake in United Therapeutics during the 1st quarter worth approximately $581,000. Quantinno Capital Management LP lifted its holdings in United Therapeutics by 19.7% during the 1st quarter. Quantinno Capital Management LP now owns 21,135 shares of the biotechnology company’s stock worth $12,533,000 after buying an additional 3,479 shares in the last quarter. Finally, Gateway Wealth Partners LLC acquired a new stake in United Therapeutics during the 1st quarter worth approximately $1,426,000. Institutional investors and hedge funds own 94.08% of the company’s stock.
Analyst Upgrades and Downgrades
UTHR has been the subject of several research reports. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $648.33.
United Therapeutics Stock Performance
Shares of United Therapeutics stock opened at $516.31 on Tuesday. United Therapeutics Corporation has a one year low of $287.64 and a one year high of $609.35. The company has a market cap of $21.92 billion, a P/E ratio of 19.06, a PEG ratio of 1.73 and a beta of 0.59. The firm has a fifty day moving average of $542.59 and a two-hundred day moving average of $533.07.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm earned $6.63 EPS. As a group, equities analysts predict that United Therapeutics Corporation will post 26.65 earnings per share for the current year.
Insider Transactions at United Therapeutics
In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,921,276.08. This represents a 34.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 492,833 shares of company stock worth $273,056,767. Insiders own 8.60% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
- Five stocks we like better than United Therapeutics
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
